Daniel Ek Builds Neko to Fix Broken Healthcare Incentives
TL;DR
Daniel Ek joins the All-In hosts to discuss Spotify's founding and his new preventive-health startup Neko, a $499 annual visit that measures 53 blood markers, images 6,000 skin spots, and includes a clinician consult. He argues the US spends 18% of GDP on healthcare because incentives are built for acute care, not prevention, and that longitudinal multi-modal data plus AI can catch chronic disease earlier. Ek favors open-source AI, but suggests compute scale should be part of the safety conversation; he is not convinced frontier-model pacing is the right frame. He also says Spotify will keep supporting open podcasting standards while building proprietary features, and shares Neko's US expansion plans.
Chapters
-
0:00 Deals and companies
Spotify's founding and path to America
The hosts introduce Daniel Ek, Spotify's co-founder, who shifted from CEO to executive chairman on January 1 after two decades building the streaming giant past 700 million active users and 300 million premium subscribers. Ek recounts starting Spotify in Sweden in 2006, at 23, when music piracy had gutted the industry, and how co-founder Martin's 'what if' questions pushed him past the licensing and copyright objections. To win over labels, he guaranteed their budget and bonus for a year and launched in 2008, then proved the model in the UK and entered the US in 2011. He closes by saying Neko is following the exact same playbook: five years of product development in Sweden, then the UK, then America.
-
6:46 Deals and companies
From CEO to investor and back to builder
Ek reveals he had no money to angel-invest before Spotify's 2018 IPO, so he spent his first 12–13 years all-in on the company. His first outside interest was healthcare, which he already talked about in an FT interview shortly after Spotify's US launch. He tried investing after the IPO but realized he loves building more than passive ownership. The hosts agree that founders who need heavy board instruction are less likely to succeed, and Ek says the alternative — finding great entrepreneurs, funding them, and letting them run — is usually better than meddling. That philosophy powers Prima Materia, the investment company he created with Shaq.
-
10:27 Science
Neko's thesis: chronic disease and data
Ek explains why healthcare became his obsession: the US spends 18% of GDP on healthcare, heart disease alone costs hundreds of billions, and chronic disease is the biggest cost driver even though early detection makes much of it preventable. The missing ingredient, he argues, is data. He and Neko co-founder Yalmer concluded that the industry agrees on moving from reactive to preventive care but has no roadmap, so they are building one around more sensors, more modalities, and longitudinal records. He compares this to Spotify: the more data the system gathers, the better its predictions, whether for the next song or an emerging health risk.
-
15:11 Science
Inside Neko's $499 preventive health visit
Ek details the Neko Gen-2 experience: a $499 visit that starts with a blood draw measuring 53 markers, then a skin rig taking 6,000 high-resolution images to index moles and lesions, plus heart, circulation, and grip-strength tests, ending with uninterrupted clinician time. Asked how this differs from One Medical or Forward, he says Neko was started in 2018, has completed more than 100,000 scans, and publishes yearly outcome data: about 1% of members have a serious undiagnosed condition. The sickest members improve the most, including people who stop smoking. Dermatology is emblematic — the average patient has 950 moles, and AI tracks changes over years better than any doctor's memory.
-
22:28 Deals and companies
Neko's economics and Ek's portfolio bets
The hosts note Neko's $499 price is comparable to Function Health and Superpower, which only do blood work, and ask why annual prevention isn't a standard American habit. Ek recommends annual visits and compares them to dentist checkups, arguing the hour should be brutally efficient. On the business model, he says vertically integrating facilities, staff, equipment, and software makes unit economics positive even at $499, and his clinics are already profitable. He also clarifies that after Spotify he is not exclusively focused on Neko: he remains executive chairman at Spotify and runs Prima Materia with Shaq, an effort to act like the greatest co-founder for new companies.
-
27:40 Policy and regulation
Why US healthcare incentives are broken
The hosts press Ek on structural costs: $15,000 ER stitches, $20,000 drugs, $6,000 for an eight-minute doctor visit. Ek says the system was built for infectious disease, so incentives reward acute fixes rather than long-term prevention. Employer-linked insurance makes it worse: a typical worker stays only a few years, so insurers have little reason to fund investments whose payback takes 10–20 years. His answer is to lower the cost of prevention so ROI decisions don't require millions of speculative dollars, and to add multimodal longitudinal data that can prove what works. Neko publishes its data annually and runs clinical trials, which he hopes will eventually show population-level differences across Sweden, the UK, and the US.
-
35:55 AI and tech
AI pacing, open-source models, and compute
Asked whether the frontier should be paced, Ek jokes that podcasters are not qualified experts — everyone became a virologist, supply-chain expert, and military expert overnight — and says every great technology has pros and cons. He wants more positive examples of AI, like tracking dermatology changes at Neko or Spotify's personalized playlists. On open-source models, he strongly supports them and cites the cost drop from $30 to 13 cents per million tokens as a democratizing force. He advocates having both frontier and fine-tuned models, which Spotify uses in parallel. The hosts add that compute scale, not just model weights, could be a guardrail; Ek says he is surprised compute is not more central to the debate, since a 100,000-GPU cluster is far more powerful than a home PC.
-
44:48 Deals and companies
Spotify, open podcast standards, and feature requests
David Sacks asks how Spotify reconciles its proprietary podcast platform with the open, RSS-based podcasting ecosystem it also helps feed. Ek says open and closed can coexist: Spotify builds destination features such as comments, but many podcasters use its tools to distribute through open standards to other platforms, because innovating within a standard requires buy-in from others. Sacks then makes two explicit feature requests from veteran podcasters: support for the going-live RSS extension and for value/donation extensions, including PayPal donations. Ek says decision-making is no longer his alone now that he is executive chairman, but promises to bring the requests to the Spotify team.
-
47:53 Deals and companies
Stardoll's rewrite and Neko's US expansion
Ek tells the origin story behind Stardoll, the Swedish company he helped rebuild before Spotify. It began as a Finnish site called Paperdoll Heaven, backed by Index Ventures and entrepreneur Matias; Danny Rhymer convinced Ek to help for 6–12 months as a favor. In Finland he found four-minute page loads, rearchitected the site, hired a new technical team, cut load time below a second, and watched traffic explode before Sequoia invested. He then left to build Spotify. The episode closes with Neko signing up at 300 Lafayette in New York, with Miami and DC coming, and a goal of launching across the US in 12 to 24 months.
Key takeaways
- Neko has completed more than 100,000 scans and discovers a serious undiagnosed medical condition in about 1% of its members, according to Daniel Ek.
- Ek argues US healthcare rewards acute fixes over prevention, and employer-linked insurance kills the ROI case for 10- to 20-year preventive investments.
- The average Neko patient has 950 moles, which Ek uses to explain why longitudinal AI imaging is superior to a doctor's memory.
- Ek was not an angel investor before Spotify's 2018 IPO because he had no liquidity; he prefers building companies to boardroom meddling.
- Ek supports open-source AI, citing a drop in token output cost from $30 to 13 cents per million, while suggesting compute scale should factor into safety debates.
- Neko's $499 visit is already unit-economics positive and its clinics profitable, Ek says, because the company is vertically integrated.
Quotes
I had hair when I began this and by the end of this, I obviously, uh, ended up being bald.
Everyone in the entire healthcare industry is in agreement that we have to take healthcare from reactive to preventative health.
The more data we're able to gather, the better predictions we're able to give you about what song to play next.
Mentioned companies and people
Companies
- Spotify
- Neko
- Prima Materia
- Stardoll
- One Medical
- Forward
- Function Health
- Superpower
- Whoop
- Oura
- Apple
- Index Ventures
- Sequoia Capital
People
- Daniel Ek
- Yalmer
- Martin
- Matias
- Danny Rhymer
Tickers
- SPOT
Topics
- healthcare costs
- preventive medicine
- chronic disease
- longitudinal health data
- AI in healthcare
- dermatology screening
- open-source AI
- AI compute governance
- US health insurance incentives
- podcasting standards
Predictions
-
Neko will expand beyond New York into Miami and DC and try to launch across the US in the next 12 to 24 months.
next 12–24 months